Evidence map›Paper›PMID 27189323›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2017

A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.

Norisuke Nakayama, Kenji Ishido, Keisho Chin, Ken Nishimura, Mizutomo Azuma, Satoshi Matsusaka, Yasuhiro Inokuchi, Satoshi Tanabe, Yosuke Kumekawa, Wasaburo Koizumi

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Nab-paclitaxel plus S-1Therapeutic advances in medical oncology · 2022
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Norisuke NakayamaDepartment of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-0815, Japan. norisuke@kcch.jp.
Kenji IshidoDepartment of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan.
Keisho ChinDepartment of Gastroenterology, Cancer Institute Hospital, Tokyo, Japan.
Ken NishimuraDepartment of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-0815, Japan.
Mizutomo AzumaDepartment of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan.
Satoshi MatsusakaDepartment of Gastroenterology, Cancer Institute Hospital, Tokyo, Japan.
Yasuhiro InokuchiDepartment of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-0815, Japan.
Satoshi TanabeDepartment of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan.
Yosuke KumekawaDepartment of Gastroenterology, Cancer Institute Hospital, Tokyo, Japan.
Wasaburo KoizumiDepartment of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Japan, S-1, an oral fluoropyrimidine, plus cisplatin is a standard regimen for advanced gastric cancer, whereas nab-paclitaxel is a treatment option. We aimed to evaluate the tolerance, pharmacokinetics, safety, and clinical efficacy of S-1 combined with nab-paclitaxel in patients with advanced gastric cancer in a phase 1 study.

methodsThe primary objective was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of S-1 plus nab-paclitaxel. The study was designed in accordance with a standard 3 + 3 method. Patients received 3-week cycles of treatment. S-1 was administered orally at 80 mg/m

resultsAmong the 16 patients enrolled, dose-limiting toxicity was observed in one patient at level 2a (S-1 80 mg/m

conclusionsBased on the present results, the RD was determined as level 3a (S-1 80 mg/m

Indexed as

AgedAlbuminsAntineoplastic Combined Chemotherapy ProtocolsDrug CombinationsFemaleFollow-Up StudiesHumansLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMaximum Tolerated DoseMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm Staging130-nm albumin-bound paclitaxelAlbuminsDrug CombinationsOxonic AcidPaclitaxelS 1 (combination)TegafurGastric cancerNab-paclitaxelS-1

Identifiers

PMID27189323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.